Delving into the Latest Updates on AY-31574 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Target-

Action-

Mechanism-

Therapeutic Areas

Digestive System Disorders

Active Indication-

Inactive Indication

Peptic Ulcer

Originator Organization

Pfizer Inc.

Active Organization-

Inactive Organization

Pfizer Inc.

License Organization-

Drug Highest PhasePendingClinical

First Approval Date-

Regulation-

Structure/Sequence

Molecular FormulaC12H8F2N2S

InChIKeyAANZPLWMKOLXIU-UHFFFAOYSA-N

CAS Registry119284-05-8

A series of substituted 2-pyridinecarbothioamides was synthesized and evaluated for gastric mucosal protectant activity in the rat. Out of this investigation N-(3,5-difluorophenyl)-2- pyridinecarbothioamide (23, AY-31,574) was identified. This compound was much more potent than sucralfate and ranitidine against ethanol-induced lesions. Compound 23 was equipotent with ranitidine against gastric injury caused by stress. Unlike ranitidine, 23 was found to be devoid of antisecretory activity in the pylorus-ligated rat model, making it a selective mucosal protectant. Such a potent selective mucosal protectant may provide a novel clinical approach in treating ulcers.

100 Deals associated with AY-31574

Login to view more data